• The strategic objective of WP3 is to design and test in the laboratory a specific paediatric formulation of hydrocortisone - Infacort® - for use in neonates and infants. The formulation will be made to Good Manufacturing Practice (GMP) guidelines and will be used for clinical trials in WP5.

  • Work Package 3

    The work package leader is Glatt GmbH with participation from ADD Advanced Drug Delivery Technologies AG and Diurnal Limited.

  • Work Package 3

    • 3.1 Develop Infacort® formulation for clinical manufacture
    • 3.2 Manufacture and release testing of Infacort®
    • 3.3 Complete long-term stability studies on Infacort®
  • Work Package 3

    Deliverables
    Status
    Formulation Development
     
    Analytical Techniques
     
    Stability Studies
     
    Lead Formulation Nomination
     
    Clinical Manufacture
     
    Long-Term Stability Studies